Skip to main content
Top
Published in:

03-01-2024 | Opioids | Anesthesia, Pain Management and Long-term Outcomes (VNR Gottumukkala and ER Mariano, Section Editors)

Anesthetic Techniques and Long-Term Oncological Outcomes

Authors: Jodi-Ann Oliver, Lori-Ann Oliver, Juan P. Cata, Vijaya Gottumukkala

Published in: Current Anesthesiology Reports | Issue 1/2024

Login to get access

Abstract

Purpose of Review

Cancer is a leading cause of death, accounting for nearly one in six deaths worldwide. Surgery is a critical intervention in cancer care since it provides a chance of cure or can be used to relieve symptoms in patients with advanced malignancies. Anesthesia (general, regional, or local) and analgesia in any of its delivery modes play critical roles in the treatment and palliation of cancers.

Recent Findings

Experimental data demonstrate that surgery itself and anesthetics can promote the growth of micro-metastatic diseases and the seeding of circulating cancer cells, thereby facilitating cancer progression. While this theory originates from in vitro and animal studies, evidence in humans has remained controversial until recently.

Summary

In this report, we summarize current published evidence on the impact of anesthetics and opioids on cancer progression. We focus our discussion on published human studies with special emphasis on randomized controlled trials.
Literature
1.
go back to reference Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
3.
go back to reference Hiller JG, et al. Perioperative events influence cancer recurrence risk after surgery. Nat Rev Clin Oncol. 2018;15(4):205–18.PubMedCrossRef Hiller JG, et al. Perioperative events influence cancer recurrence risk after surgery. Nat Rev Clin Oncol. 2018;15(4):205–18.PubMedCrossRef
4.
go back to reference Melamed R, et al. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. Anesthesia Analgesia. 2003;97(5):1331–1339. Melamed R, et al. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. Anesthesia Analgesia. 2003;97(5):1331–1339.
5.
go back to reference Bar-Yosef S, et al. Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology. 2001;94(6):1066–73.PubMedCrossRef Bar-Yosef S, et al. Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology. 2001;94(6):1066–73.PubMedCrossRef
6.
go back to reference Yap A, et al. Anesthetic technique and cancer outcomes: a meta-analysis of total intravenous versus volatile anesthesia. Can J Anaesth. 2019;66(5):546–61.PubMedCrossRef Yap A, et al. Anesthetic technique and cancer outcomes: a meta-analysis of total intravenous versus volatile anesthesia. Can J Anaesth. 2019;66(5):546–61.PubMedCrossRef
7.
go back to reference Zhu M, et al. Isoflurane enhances the malignant potential of glioblastoma stem cells by promoting their viability, mobility in vitro and migratory capacity in vivo. Br J Anaesth. 2016;116(6):870–7.PubMedCrossRef Zhu M, et al. Isoflurane enhances the malignant potential of glioblastoma stem cells by promoting their viability, mobility in vitro and migratory capacity in vivo. Br J Anaesth. 2016;116(6):870–7.PubMedCrossRef
8.
9.
go back to reference Pang Q-Y, et al. Comparison of outcomes after breast cancer surgery between inhalational and propofol-based intravenous anaesthesia: a systematic review and meta-analysis. J Pain Res. 2021;14:2165–77.PubMedPubMedCentralCrossRef Pang Q-Y, et al. Comparison of outcomes after breast cancer surgery between inhalational and propofol-based intravenous anaesthesia: a systematic review and meta-analysis. J Pain Res. 2021;14:2165–77.PubMedPubMedCentralCrossRef
10.
go back to reference •• Wigmore TJ, Mohammed K, Jhanji S. Long-term survival for patients undergoing volatile versus IV anesthesia for cancer surgery: a retrospective analysis. Anesthesiology, 2016;124(1): 69–79. Although a retrospective study, this was a large study which after prospective matching and adjustment for known confounding factors demonstrated improved survival in patients undergoing elective cancer surgery with propofol based TIVA compared to volatile anesthesia. This biological plausibility generated great interest in the study of the effects of anesthetic agents on cancer outcomes. •• Wigmore TJ, Mohammed K, Jhanji S. Long-term survival for patients undergoing volatile versus IV anesthesia for cancer surgery: a retrospective analysis. Anesthesiology, 2016;124(1): 69–79. Although a retrospective study, this was a large study which after prospective matching and adjustment for known confounding factors demonstrated improved survival in patients undergoing elective cancer surgery with propofol based TIVA compared to volatile anesthesia. This biological plausibility generated great interest in the study of the effects of anesthetic agents on cancer outcomes.
11.
go back to reference Makito KMK, Fushimi K, Yasunaga H. Volatile versus total intravenous anesthesia for cancer prognosis in patients having digestive cancer surgery: a nationwide retrospective cohort study. Anesthesiology. 2020;133(4):764–73.PubMedCrossRef Makito KMK, Fushimi K, Yasunaga H. Volatile versus total intravenous anesthesia for cancer prognosis in patients having digestive cancer surgery: a nationwide retrospective cohort study. Anesthesiology. 2020;133(4):764–73.PubMedCrossRef
12.
go back to reference Cao S-J, et al. Long-term survival in older patients given propofol or sevoflurane anaesthesia for major cancer surgery: follow-up of a multicentre randomised trial. Br J Anaesth. 2023;131(2):266–75.PubMedCrossRef Cao S-J, et al. Long-term survival in older patients given propofol or sevoflurane anaesthesia for major cancer surgery: follow-up of a multicentre randomised trial. Br J Anaesth. 2023;131(2):266–75.PubMedCrossRef
13.
go back to reference Lovett-Carter D, et al. The effect of systemic lidocaine on post-operative opioid consumption in ambulatory surgical patients: a meta-analysis of randomized controlled trials. Perioper Med. 2021;10(1):11.CrossRef Lovett-Carter D, et al. The effect of systemic lidocaine on post-operative opioid consumption in ambulatory surgical patients: a meta-analysis of randomized controlled trials. Perioper Med. 2021;10(1):11.CrossRef
14.
go back to reference Cata JP, et al. Lidocaine stimulates the function of natural killer cells in different experimental settings. Anticancer Res. 2017;37(9):4727–32.PubMed Cata JP, et al. Lidocaine stimulates the function of natural killer cells in different experimental settings. Anticancer Res. 2017;37(9):4727–32.PubMed
15.
go back to reference Ramirez MF, Tran P, Cata JP. The effect of clinically therapeutic plasma concentrations of lidocaine on natural killer cell cytotoxicity. Reg Anesth Pain Med. 2015;40(1):43–8.PubMedCrossRef Ramirez MF, Tran P, Cata JP. The effect of clinically therapeutic plasma concentrations of lidocaine on natural killer cell cytotoxicity. Reg Anesth Pain Med. 2015;40(1):43–8.PubMedCrossRef
16.
go back to reference Galoş EV, et al. Neutrophil extracellular trapping and angiogenesis biomarkers after intravenous or inhalation anaesthesia with or without intravenous lidocaine for breast cancer surgery: a prospective, randomised trial. Br J Anaesth. 2020;125(5):712–21.PubMedCrossRef Galoş EV, et al. Neutrophil extracellular trapping and angiogenesis biomarkers after intravenous or inhalation anaesthesia with or without intravenous lidocaine for breast cancer surgery: a prospective, randomised trial. Br J Anaesth. 2020;125(5):712–21.PubMedCrossRef
17.
go back to reference Li CY, et al. Lidocaine attenuates monocyte chemoattractant protein-1 production and chemotaxis in human monocytes: possible mechanisms for its effect on inflammation. Anesth Analg. 2003;97(5):1312–6.PubMedCrossRef Li CY, et al. Lidocaine attenuates monocyte chemoattractant protein-1 production and chemotaxis in human monocytes: possible mechanisms for its effect on inflammation. Anesth Analg. 2003;97(5):1312–6.PubMedCrossRef
18.
go back to reference Zhang H, et al. Effects of intravenous infusion of lidocaine on short-term outcomes and survival in patients undergoing surgery for ovarian cancer: a retrospective propensity score matching study. Front Oncol 2022;11:689832. Zhang H, et al. Effects of intravenous infusion of lidocaine on short-term outcomes and survival in patients undergoing surgery for ovarian cancer: a retrospective propensity score matching study. Front Oncol 2022;11:689832.
19.
go back to reference Zhang H, et al. Intraoperative lidocaine infusion in patients undergoing pancreatectomy for pancreatic cancer: a mechanistic, multicentre randomised clinical trial. Br J Anaesth. 2022;129(2):244–53.PubMedCrossRef Zhang H, et al. Intraoperative lidocaine infusion in patients undergoing pancreatectomy for pancreatic cancer: a mechanistic, multicentre randomised clinical trial. Br J Anaesth. 2022;129(2):244–53.PubMedCrossRef
20.
go back to reference Zhang H, et al. Association between intraoperative intravenous lidocaine infusion and survival in patients undergoing pancreatectomy for pancreatic cancer: a retrospective study. British J Anaesth. 2020;125(2):141–8.CrossRef Zhang H, et al. Association between intraoperative intravenous lidocaine infusion and survival in patients undergoing pancreatectomy for pancreatic cancer: a retrospective study. British J Anaesth. 2020;125(2):141–8.CrossRef
21.
go back to reference Lavon H, et al. Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers. Br J Anaesth. 2018;120(1):188–96.PubMedCrossRef Lavon H, et al. Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers. Br J Anaesth. 2018;120(1):188–96.PubMedCrossRef
22.
go back to reference Chen W, et al. Dexmedetomidine provides type-specific tumour suppression without tumour-enhancing effects in syngeneic murine models. Br J Anaesth. 2023;130(2):142–53.PubMedCrossRef Chen W, et al. Dexmedetomidine provides type-specific tumour suppression without tumour-enhancing effects in syngeneic murine models. Br J Anaesth. 2023;130(2):142–53.PubMedCrossRef
23.
go back to reference Cata J, et al. Intraoperative use of dexmedetomidine is associated with decreased overall survival after lung cancer surgery. J Anaesthesiol Clin Pharmacol. 2017;33(3):317–23.PubMedPubMedCentralCrossRef Cata J, et al. Intraoperative use of dexmedetomidine is associated with decreased overall survival after lung cancer surgery. J Anaesthesiol Clin Pharmacol. 2017;33(3):317–23.PubMedPubMedCentralCrossRef
24.
go back to reference Hu J, et al. Association between intraoperative dexmedetomidine and all-cause mortality and recurrence after laparoscopic resection of colorectal cancer: follow-up analysis of a previous randomized controlled trial. Front Oncol 2023;13:906514. Hu J, et al. Association between intraoperative dexmedetomidine and all-cause mortality and recurrence after laparoscopic resection of colorectal cancer: follow-up analysis of a previous randomized controlled trial. Front Oncol 2023;13:906514.
25.
go back to reference Xing M-W, et al. Effect of intraoperative dexmedetomidine on long-term survival in older patients after major noncardiac surgery: 3-year follow-up of a randomized trial. J Clin Anesthesia 2023;86. Xing M-W, et al. Effect of intraoperative dexmedetomidine on long-term survival in older patients after major noncardiac surgery: 3-year follow-up of a randomized trial. J Clin Anesthesia 2023;86.
26.
go back to reference Connolly JG, et al. Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma. Br J Anaesth. 2021;127(1):75–84.PubMedPubMedCentralCrossRef Connolly JG, et al. Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma. Br J Anaesth. 2021;127(1):75–84.PubMedPubMedCentralCrossRef
27.
go back to reference Forget P, et al. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg. 2010;110(6):1630–5.PubMedCrossRef Forget P, et al. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg. 2010;110(6):1630–5.PubMedCrossRef
28.
go back to reference Cho JS, et al. The immunomodulatory effect of ketamine in colorectal cancer surgery: a randomized-controlled trial. Canadian J Anesthesia/J Canadien d'Anesthésie. 2021;68(5):683–92.CrossRef Cho JS, et al. The immunomodulatory effect of ketamine in colorectal cancer surgery: a randomized-controlled trial. Canadian J Anesthesia/J Canadien d'Anesthésie. 2021;68(5):683–92.CrossRef
29.
go back to reference •• Sessler DI, et al. Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. Lancet 2019;394(10211): 1807–1815. This was the first large multicenter randomized controlled trial performed to evaluate the effect of regional anesthesia-analgesia with paravertebral blocks and propofol sedation on recurrence rates after breast cancer surgery. •• Sessler DI, et al. Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. Lancet 2019;394(10211): 1807–1815. This was the first large multicenter randomized controlled trial performed to evaluate the effect of regional anesthesia-analgesia with paravertebral blocks and propofol sedation on recurrence rates after breast cancer surgery.
30.
go back to reference Xu Z-Z, et al. Epidural anesthesia–analgesia and recurrence-free survival after lung cancer surgery: a randomized trial. Anesthesiology. 2021;135(3):419–32.PubMedCrossRef Xu Z-Z, et al. Epidural anesthesia–analgesia and recurrence-free survival after lung cancer surgery: a randomized trial. Anesthesiology. 2021;135(3):419–32.PubMedCrossRef
31.
go back to reference Aloia TA, et al. A randomized controlled trial of postoperative thoracic epidural analgesia versus intravenous patient-controlled analgesia after major hepatopancreatobiliary surgery. Ann Surg. 2017;266(3):545–54.PubMedCrossRef Aloia TA, et al. A randomized controlled trial of postoperative thoracic epidural analgesia versus intravenous patient-controlled analgesia after major hepatopancreatobiliary surgery. Ann Surg. 2017;266(3):545–54.PubMedCrossRef
32.
33.
go back to reference Xing W, et al. Lidocaine induces apoptosis and suppresses tumor growth in human hepatocellular carcinoma cells in vitro and in a xenograft model in vivo. Anesthesiology. 2017;126(5):868–81.PubMedCrossRef Xing W, et al. Lidocaine induces apoptosis and suppresses tumor growth in human hepatocellular carcinoma cells in vitro and in a xenograft model in vivo. Anesthesiology. 2017;126(5):868–81.PubMedCrossRef
34.
go back to reference Sessler DI. Does regional analgesia reduce the risk of cancer recurrence? A hypothesis. Eur J Cancer Prev. 2008;17(3):269–72.PubMedCrossRef Sessler DI. Does regional analgesia reduce the risk of cancer recurrence? A hypothesis. Eur J Cancer Prev. 2008;17(3):269–72.PubMedCrossRef
35.
go back to reference Illias AM, et al. Association of regional anesthesia with oncological outcomes in patients receiving surgery for bladder cancer: a meta-analysis of observational studies. Front Oncol 2023;13:1097637. Illias AM, et al. Association of regional anesthesia with oncological outcomes in patients receiving surgery for bladder cancer: a meta-analysis of observational studies. Front Oncol 2023;13:1097637.
36.
go back to reference Cata JP, et al. The impact of paravertebral block analgesia on breast cancer survival after surgery. Reg Anesth Pain Med. 2016;41(6):696–703.PubMedCrossRef Cata JP, et al. The impact of paravertebral block analgesia on breast cancer survival after surgery. Reg Anesth Pain Med. 2016;41(6):696–703.PubMedCrossRef
37.
go back to reference Exadaktylos AK, et al. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 2006;105(4):660–4.PubMedCrossRef Exadaktylos AK, et al. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 2006;105(4):660–4.PubMedCrossRef
38.
go back to reference Christopherson R, et al. Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg. 2008;107(1):325–32.PubMedCrossRef Christopherson R, et al. Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg. 2008;107(1):325–32.PubMedCrossRef
39.
go back to reference Myles PS, et al. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. BMJ. 2011;342: d1491.PubMedCrossRef Myles PS, et al. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. BMJ. 2011;342: d1491.PubMedCrossRef
40.
go back to reference Yu L, et al. Perioperative pectoral nerve block type II and postoperative recurrence in breast cancer: a randomized controlled trial. BMC Surg. 2022;22(1):447.PubMedPubMedCentralCrossRef Yu L, et al. Perioperative pectoral nerve block type II and postoperative recurrence in breast cancer: a randomized controlled trial. BMC Surg. 2022;22(1):447.PubMedPubMedCentralCrossRef
41.
go back to reference Karmakar MK, et al. Survival analysis of patients with breast cancer undergoing a modified radical mastectomy with or without a thoracic paravertebral block: a 5-year follow-up of a randomized controlled trial. Anticancer Res. 2017;37(10):5813–20.MathSciNetPubMed Karmakar MK, et al. Survival analysis of patients with breast cancer undergoing a modified radical mastectomy with or without a thoracic paravertebral block: a 5-year follow-up of a randomized controlled trial. Anticancer Res. 2017;37(10):5813–20.MathSciNetPubMed
42.
go back to reference Du YT, et al. Long-term survival after combined epidural-general anesthesia or general anesthesia alone: follow-up of a randomized trial. Anesthesiology. 2021;135(2):233–45.PubMedCrossRef Du YT, et al. Long-term survival after combined epidural-general anesthesia or general anesthesia alone: follow-up of a randomized trial. Anesthesiology. 2021;135(2):233–45.PubMedCrossRef
43.
go back to reference Falk W, et al. Comparison between epidural and intravenous analgesia effects on disease-free survival after colorectal cancer surgery: a randomised multicentre controlled trial. Br J Anaesth. 2021;127(1):65–74.PubMedPubMedCentralCrossRef Falk W, et al. Comparison between epidural and intravenous analgesia effects on disease-free survival after colorectal cancer surgery: a randomised multicentre controlled trial. Br J Anaesth. 2021;127(1):65–74.PubMedPubMedCentralCrossRef
44.
go back to reference Badwe RA, et al. Effect of peritumoral infiltration of local anesthetic before surgery on survival in early breast cancer. J Clin Oncol. 2023;41(18):3318–28.PubMedCrossRef Badwe RA, et al. Effect of peritumoral infiltration of local anesthetic before surgery on survival in early breast cancer. J Clin Oncol. 2023;41(18):3318–28.PubMedCrossRef
45.
go back to reference Gorur A, et al. Mu-opioid receptor activation promotes in vitro and in vivo tumor growth in head and neck squamous cell carcinoma. Life Sci. 2021;278:119541.PubMedCrossRef Gorur A, et al. Mu-opioid receptor activation promotes in vitro and in vivo tumor growth in head and neck squamous cell carcinoma. Life Sci. 2021;278:119541.PubMedCrossRef
46.
go back to reference Cata JP, et al. The µ‐opioid receptor in cancer and its role in perineural invasion: a short review and new evidence. Adv Biol 2022;2200020. Cata JP, et al. The µ‐opioid receptor in cancer and its role in perineural invasion: a short review and new evidence. Adv Biol 2022;2200020.
47.
go back to reference Zylla D, et al. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. Br J Anaesth. 2014;113:i109–16.PubMedPubMedCentralCrossRef Zylla D, et al. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. Br J Anaesth. 2014;113:i109–16.PubMedPubMedCentralCrossRef
48.
go back to reference Zylla D, et al. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer. 2013;119(23):4103–10.PubMedCrossRef Zylla D, et al. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer. 2013;119(23):4103–10.PubMedCrossRef
49.
go back to reference Zhang H, et al. Increased mu-opioid receptor expression is associated with reduced disease-free and overall survival in laryngeal squamous cell carcinoma. Br J Anaesth. 2020;125(5):722–9.PubMedCrossRef Zhang H, et al. Increased mu-opioid receptor expression is associated with reduced disease-free and overall survival in laryngeal squamous cell carcinoma. Br J Anaesth. 2020;125(5):722–9.PubMedCrossRef
50.
go back to reference Zhang H, et al. Association of mu-opioid receptor(MOR) expression and opioids requirement with survival in patients with stage I-III pancreatic ductal adenocarcinoma. Front Oncol. 2021;11: 686877.PubMedPubMedCentralCrossRef Zhang H, et al. Association of mu-opioid receptor(MOR) expression and opioids requirement with survival in patients with stage I-III pancreatic ductal adenocarcinoma. Front Oncol. 2021;11: 686877.PubMedPubMedCentralCrossRef
51.
go back to reference Diaz-Cambronero O, et al. Mu opioid receptor 1 (MOR-1) expression in colorectal cancer and oncological long-term outcomes: a five-year retrospective longitudinal cohort study. Cancers (Basel). 2020;12(1):134.PubMedCrossRef Diaz-Cambronero O, et al. Mu opioid receptor 1 (MOR-1) expression in colorectal cancer and oncological long-term outcomes: a five-year retrospective longitudinal cohort study. Cancers (Basel). 2020;12(1):134.PubMedCrossRef
52.
go back to reference Paice JA, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(27):3325–45.PubMedCrossRef Paice JA, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(27):3325–45.PubMedCrossRef
53.
go back to reference Cata JP, et al. Intraoperative opioids use for laryngeal squamous cell carcinoma surgery and recurrence: a retrospective study. J Clin Anesth. 2015;27(8):672–9.PubMedCrossRef Cata JP, et al. Intraoperative opioids use for laryngeal squamous cell carcinoma surgery and recurrence: a retrospective study. J Clin Anesth. 2015;27(8):672–9.PubMedCrossRef
54.
go back to reference Cata JP, et al. A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection. Cancer Med. 2014;3(4):900–8.PubMedPubMedCentralCrossRef Cata JP, et al. A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection. Cancer Med. 2014;3(4):900–8.PubMedPubMedCentralCrossRef
55.
go back to reference Nelson DB, et al. Persistent opioid use is associated with worse survival after lobectomy for stage i non-small cell lung cancer. Pain. 2019;160(10):2365–73.PubMedCrossRef Nelson DB, et al. Persistent opioid use is associated with worse survival after lobectomy for stage i non-small cell lung cancer. Pain. 2019;160(10):2365–73.PubMedCrossRef
56.
go back to reference Steele GL, et al. Impact of pain, opioids, and the mu-opioid receptor on progression and survival in patients with newly diagnosed stage IV pancreatic cancer. Am J Clin Oncol. 2020;43:591–7.PubMedCrossRef Steele GL, et al. Impact of pain, opioids, and the mu-opioid receptor on progression and survival in patients with newly diagnosed stage IV pancreatic cancer. Am J Clin Oncol. 2020;43:591–7.PubMedCrossRef
57.
go back to reference Cronin-Fenton D. Opioids and breast cancer recurrence. Curr Opin Support Palliat Care. 2019;13(2):88–93.PubMedCrossRef Cronin-Fenton D. Opioids and breast cancer recurrence. Curr Opin Support Palliat Care. 2019;13(2):88–93.PubMedCrossRef
58.
go back to reference Patino MA, et al. The impact of intraoperative opioid use on survival after oral cancer surgery. Oral Oncol. 2017;74:1–7.PubMedCrossRef Patino MA, et al. The impact of intraoperative opioid use on survival after oral cancer surgery. Oral Oncol. 2017;74:1–7.PubMedCrossRef
59.
go back to reference Owusu-Agyemang P, et al. Assessing the survival impact of perioperative opioid consumption in children and adolescents undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Paediatr Anaesth. 2017;27(6):648–56.PubMedCrossRef Owusu-Agyemang P, et al. Assessing the survival impact of perioperative opioid consumption in children and adolescents undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Paediatr Anaesth. 2017;27(6):648–56.PubMedCrossRef
60.
go back to reference Janku F, et al. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol. 2016;27(11):2032–8.PubMedPubMedCentralCrossRef Janku F, et al. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol. 2016;27(11):2032–8.PubMedPubMedCentralCrossRef
61.
go back to reference Vijayakumar J, et al. An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer. Invest New Drugs. 2022;41(1):70–5.PubMedPubMedCentralCrossRef Vijayakumar J, et al. An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer. Invest New Drugs. 2022;41(1):70–5.PubMedPubMedCentralCrossRef
Metadata
Title
Anesthetic Techniques and Long-Term Oncological Outcomes
Authors
Jodi-Ann Oliver
Lori-Ann Oliver
Juan P. Cata
Vijaya Gottumukkala
Publication date
03-01-2024
Publisher
Springer US
Published in
Current Anesthesiology Reports / Issue 1/2024
Electronic ISSN: 2167-6275
DOI
https://doi.org/10.1007/s40140-023-00605-w

Other articles of this Issue 1/2024

Anesthetic Exposure During Early Childhood and Neurodevelopmental Outcomes: Our Current Understanding

  • General Anesthesia
  • Anesthesia, Pain Management and Long-term Outcomes (VNR Gottumukkala and ER Mariano, Section Editors)

Environmentally Sustainable Anesthesia to Minimize Risks from Climate Change: a Societal Imperative or too Lofty a Goal?

  • Climate Change
  • Anesthesia, Pain Management and Long-term Outcomes (VNR Gottumukkala and ER Mariano, Section Editors)

Monitoring the Depth of Neuromuscular Blockade

  • Tetanus
  • Neuromuscular Blockade (CA Lien, Section Editor)

Postsurgical Recovery and Long-Term Outcomes: What Should We Be Measuring?

  • Anesthesia, Pain Management and Long-term Outcomes (VNR Gottumukkala and ER Mariano, Section Editors)